Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats

Neurobiology of Learning and Memory

Volumn 80, Issue 1, 2003, Pages 63-79

  De Bruin, N M W J ^a,b   Kiliaan, A J ^a,c   De Wilde, M C ^a   Broersen, L M ^a  

^a NUMICO RESEARCH   (Netherlands)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 Choice serial reaction time (5 CSRT); Choline; Delayed non matching to position (DNMTP); Memory; Morris water maze; Open field; Rats; Selective attention; Spatial learning; Spontaneously hypertensive rats (SHR); Uridine; Uridine 5 monophosphate 2Na (UMP)

Indexed keywords

C 7527; CHOLINE; URIDINE PHOSPHATE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; RAT; REACTION TIME; SHORT TERM MEMORY; SPONTANEOUSLY HYPERTENSIVE RAT; TASK PERFORMANCE;

EID: 0037739814     PISSN: 10747427     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7427(03)00024-8     Document Type: Article

References (88)

1. Agnoli A., Ruggieri S.et al. New strategies in the management of Parkinson's disease: A biological approach using a phospholipid precursor (CDP-choline). Neuropsychobiology. 8:1982;289-296.
2. Agut J., Ortiz J.A. Age-related changes in memory and their pharmacologic modulation. Annales of New York Academy Sciences. 640:1991;295-297.
3. ′ ) diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine Neuropharmacology. 23:1984;1403-1406.
4. ′ -diphosphate choline administration to rats increases brain phospholipid levels Annales of New York Academy Sciences. 695:1993;318-320.
5. ′ )diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by microdialysis Annales of New York Academy Sciences. 920:2000;332-335.
6. Alvarez X.A., Laredo M., Corzo D.et al. Citicoline improves memory performance in elderly subjects. Methods Find Experimental and Clinical Pharmacology. 19:1997;201-210.
7. Alvarez X., Mouzo A.R.et al. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Experimental and Clinical Pharmacology. 21:1999;633-644.
8. Alvarez X.A., Sampedro C., Lozano R., Cacabelos R. Citicoline protects hippocampal neurons against apoptosis induced by brain β-amyloid deposits plus cerebral hypofusion in rats. Methods Find Experimental and Clinical Pharmacology. 21:1999;535-540.
9. Amini, B., Yang, P., Swann, A. C., & Dafny, N. (2001). Strain differences in diurnal pattern of locomotor activity and the response to methylphenidate. Society of Neuroscicence Abstracts. 960.5.
10. Anstey K., Christensen H. Education, activity, health, blood pressure and apolipoprotein E as predictors of cognitive change in old age: A review. Gerontology. 46:2000;163-177.
11. Aronowski J., Strong R., Grotta J.C. Citicoline for treatment of experimental focal ischemia: Histologic and behavioral outcome. Neurological Research. 18:1996;570-574.
12. Berger D.F., Sagvolden T. Sex differences in operant discrimination behavior in an animal model of attention-deficit hyperactivity disorder. Behavioral Brain Research. 94:1998;73-82.
13. Birkenhager W.H., Forette F., Seux M.L., Wang J.G., Staessen J.A. Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Archives of Internal Medicine. 161:2001;152-156.
14. Boismare, F., Le Poncin Lefitte, M., & Rapin, J.R. (1978). Hemodynamic, functional, and biochemical effects of hypobaric hypoxia in rats treated with cytidine diphosphocholine. Presented at the Comptes rendus des seances de las Societe de Biologie 72, p. 651.
15. Boix F., Qiao S.W., Kolpus T., Sagvolden T. Chronic L-deprenyl treatment alters brain monoamine levels and reduces impulsiveness in an animal model of attention-deficit/hyperactivity disorder. Behavioral Brain Research. 94:1998;153-162.
16. Boudouresques, A. B., & Michel, B. 1980. Therapeutic conduct in light of a cerebral vascular accident and the use of CDP-choline. Presented at the International Symposium: Brain suffering and precursors of phospholipids, Paris.
17. Broersen L.M., Heinsbroek R.P., de Bruin J.P., Joosten R.N., van Hest A., Olivier B. Effects of local application of dopaminergic drugs into the dorsal part of the medial prefrontal cortex of rats in a delayed matching to position task: Comparison with local cholinergic blockade. Brain Research. 645:1994;113-122.
18. Broersen L.M., Heinsbroek R.P., de Bruin J.P., Uylings H.B., Olivier B. The role of the medial prefrontal cortex of rats in short-term memory functioning: Further support for involvement of cholinergic, rather than dopaminergic mechanisms. Brain Research. 674:1995;221-229.
19. Bull E., Reavill C., Hagan J.J., Overend P., Jones D.N. Evaluation of the spontaneously hypertensive rat as a model of attention deficit hyperactivity disorder: Acquisition and performance of the DRL-60s test. Behavioral Brain Research. 109:2000;27-35.
20. Caamano J., Gomez M.J.et al. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer's disease. Methods Find Exp. Clin. Pharmacol. 16:1994;211-218.
21. Cacabelos, R., Caamano, Gomez, M. J., Fernandez-Novoa, L., Franco-Maside, A., & Alvarez, X. A. (1996). Therapeutic effects of CDP-choline in Alzheimer's disease.
22. Carli M., Samanin R. Serotonin-2 receptor agonists and serotonergic anorectic drugs affect rats' performance differently in a five-choice serial reaction time task. Psychopharmacology. 106:1992;228-234.
23. Clark W., Gunion-Rinker L., Lessov N., Hazel K. Citicoline treatment for experimental intracerebral hemorrhage in mice. Stroke. 29:1998;2136-2140.
24. Clark W.M., Warach S.J., Pettigrew L.C., Gammans R.E., Sabounjian L.A. A randomized dose-response trial of citicoline in acute ischemic stroke patients. Neurology. 49:1997;671-678.
25. Cohen E.L., Wurtman R.J. Brain acetylcholine: Control by dietary choline. Science. 191:1976;561-562.
26. Corso A., Arena M., Ventimiglia A., Bizzarro G., Campo G., Radalica F. CDP-choline for cerebrovascular disorders: Clinical evaluation and evaluation of electrophysiological symptomology. Clin. Ther. 102:1982;379-386.
27. Coviella I.L., Wurtman R.J. Enhancement by cytidine of membrane phospholipid synthesis. Journal of Neurochemistry. 59:1992;338-343.
28. De Medio G.E., Brunett M., Dorman R.V. Phospholipid metabolism during central and peripheral damage and recovery in nervous tissue. Birth Defects Original article series. 19:1983;175-187.
29. Dixon C.E., Ma X., Marion D.W. Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. Journal of Neurotrauma. 14:1997;161-169.
30. Dorman R.V., Dabrowiecki Z., DeMedio G.E., Trovarelli G., Porcellati G., Horroks L.A. Control of lipid metabolism in ischemic brain CDP amines. Horroks L.A., Ansell G.B., Porcellati G. Phospholipids in the Nervous System. Vol. I: Metabolism. 1982;123-135 Raven Press Publishers, New York.
31. Dunnett S.B. Role of prefrontal cortex and striatal output systems in short-term memory deficits associated with ageing, basal forebrain lesions, and cholinergic-rich grafts. Canadian Journal of Psycholology. 44:1990;210-232.
32. Dunnett S.B., Evenden J.L., Iversen S.D. Delay-dependent short-term memory deficits in aged rats. Psychopharmacology (Berl). 96:1988;174-180.
33. Dunnett S.B., Wareham A.T., Torres E.M. Cholinergic blockade in prefrontal cortex and hippocampus disrupts short-term memory in rats. Neuroreport. 1:1990;61-64.
34. Forette F., Seux M., Thijs L., Le-Divenah A., Perol M.B., Rigaud A.S., Latour F., Bouchacourt P., Staessen J.A. Detection of cerebral aging, an absolute need: Predictive value of cognitive status. European Neurology. 39(Suppl. 1):1998;2-6.
35. Freedman R., Hall M., Adler L.E., Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biological Psychiatry. 38:1995;22-33.
36. Gattu M., Pauly J.R., Boss K.L., Summers J.B., Buccafusco J.J. Cognitive impairment in spontaneously hypertensive rats: Role of central nicotinic receptors.I. Brain Research. 771:1997;89-103.
37. Gattu M., Terry A.V. Jr., Pauly J.R., Buccafusco J.J. Cognitive impairment in spontaneously hypertensive rats: Role of central nicotinic receptors. Part II. Brain Research. 771:1997;104-114.
38. Gimenez R., Soler S., Aguilar J. Cytidine diphosphate choline administration activates brain cytidine triphosphate: Phosphocholine cytidylytransferase in aged rats. Neuroscience Letters. 273:1999;163-166.
39. Goyas, J. Y., Bastard, J., & Missoum, A. (1980). Results after 90 days of stroke treatment with CDP-choline, concerning a double blind test. Presented at the International Symposium: Brain suffering and precursors of phospholipids, Paris.
40. Hamdorf G., Cervos-Navarro J. Study of the effects of oral administration of CDP-choline on open-field behaviour under conditions of chronic hypoxia. Arzneimittelforschung. 40:1990;519-522.
41. Hellstrom-Lindahl E., Court J.A. Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. Behavioral Brain Research. 113:2000;159-168.
42. Hendley E.D. WKHA rats with genetic hyperactivity and hyperreactivity to stress: A review. Neuroscience and Biobehavioral Review. 24:2000;41-44.
43. Hirsch M.J., Crowden J.H., Wurtman R.J. Relations between dietary choline or lecithin intake, serum choline levels, and various metabolic indices. Metabolism. 27:1978;953-960.
44. Hunziker M.H., Saldana R.L., Neuringer A. Behavioral variability in SHR and WKY rats as a function of rearing environment and reinforcement contingency. Journal of the Experimental Analysis of Behavior. 65:1996;129-144.
45. Johansen, E. B., & Sagvolden, T., (2001). Effects of ICSS reinforcement parameters on the hyperactive behavior of the Spontaneously Hypertensive rat (SHR), an animal model of ADHD. Society of Neuroscience Abstracts 533.18.
46. Jones S., Sudweeks S., Yakel J.L. Nicotinic receptors in the brain: Correlating physiology with function. Trends in Neuroscience. 22:1999;555-561.
47. Kakihana M., Fukuda N., Suno M., Nagaoka A. Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia. Stroke. 19:1988;217-222.
48. King J.A., Barkley R.A., Delville Y., Ferris C.F. Early androgen treatment decreases cognitive function and catecholamine innervation in an animal model of ADHD. Behavioral Brain Research. 107:2000;35-43.
49. Kivipelto M., Helkala E.L., Hanninen T., Laakso M.P., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. Neurology. 56:2001;1683-1689.
50. Knapp S., Wurtman R.J. Enhancement of free fatty acid incorporation into phospholipids by choline plus cytidine. Brain Research. 822(1-2):1999;52-59.
51. Knopman D., Boland L.L., Mosley T., Howard G., Liao D., Szklo M., McGovern P., Folsom A.R. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 56:2001;42-48.
52. Lopez-Coviella I., Wurtman R.J. Enhancement by cytidine of brain membrane phospholipid synthesis. Journal of Neurochemistry. 59:1992;338-343.
53. ′ -cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels Journal of Neurochemistry. 65:1992;889-894.
54. ′ -cytidinediphosphocholine can affect brain phospholipid composition by increasing choline and cytidine plasma levels Journal of Neurochemistry. 65:1995;889-894.
55. ′ -diphosphocholine (CDP-choline) following oral and intravenous administration to the human and the rat Neurochemistry International. 11:1987;293-297.
56. Meneses A., Castillo C., Ibarra M., Hong E. Effects of aging and hypertension on learning, memory and activity in rats. Physiology & Behavior. 60:1996;341-345.
57. Meneses A., Hong E. Spontaneously hypertensive rats: A potential model to identify drugs for treatment of learning disorders. Hypertension. 31:1998;968-972.
58. Meyer J.S., Rauch G.M., Rauch R.A., Haque A., Crawford K. Cardiovascular and other risk factors for Alzheimer's disease and vascular dementia. Annales of New York Academy Sciences. 903:2000;411-423.
59. Meyer J.S., Rauch G., Rauch R.A., Haque A. Risk factors for cerebral hypoperfusion, mild cognitive impairment, and dementia. Neurobiology of Aging. 21:2000;161-169.
60. Millington W.R., Wurtman R.J. Choline administration elevates brain phosphorylcholine concentrations. Journal of Neurochemistry. 38:1982;1748-1752.
61. Mori S., Kato M., Fujishima M. Impaired maze learning and cerebral glucose utilization in aged hypertensive rats. Hypertension. 25:1995;545-553.
62. Muir J.L. Attention and stimulus processing in the rat. Brain Research and Cognition Brain Research. 3:1996;215-225.
63. Muir J.L., Everitt B.J., Robbins T.W. The cerebral cortex of the rat and visual attentional function: Dissociable effects of mediofrontal, cingulate, anterior dorsolateral, and parietal cortex lesions on a five-choice serial reaction time task. Cerebral Cortex. 6:1996;470-481.
64. Muir J.L., Fischer W., Bjorklund A. Decline in visual attention and spatial memory in aged rats. Neurobiology of Aging. 20:1999;605-615.
65. Mykita S., Golly F., Dreyfus H., Freysz L., Massarelli R. Effect of CDP choline on hippocampal neurons in culture. Journal of Neurochemistry. 47:1986;223-231.
66. Nakamura-Palacios E.M., Caldas C.K., Fiorini A., Chagas K.D., Chagas K.N., Vasquez E.C. Deficits of spatial learning and working memory in spontaneously hypertensive rats. Behavioral Brain Research. 74:1996;217-227.
67. Nikkel, A. L., Decker, M. W., Fox, G. B., & Bitner, R. S. (2001). Spontaneously Hypertensive rat (SHR) behavior in an operant model of attention-deficit hyperactive disorder (ADHD): Possible effects of methylphenidate on impulsivity. Society of Neuroscicence Abstracts, 851.3.
68. Perry E.K., Morris C.M., Court J.A., Cheng A., Fairbairn A.F., McKeith I.G., Irving D., Brown A., Perry R.H. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology. Neuroscience. 64:1995;385-395.
69. Petkov V.D., Kehayov R.A.et al. Effects of cytidine diphosphate choline on rats with memory deficits. Arzneimittelforschung. 43:1993;822-828.
70. Quik M., Jeyarasasingam G. Nicotinic receptors and Parkinson's disease. European Journal of Pharmacology. 393:2000;223-230.
71. Russell V.A. Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behavioral Brain Research. 130:2002;191-196.
72. Russell V., Allie S., Wiggins T. Increased noradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder - the spontaneously hypertensive rat. Behavioral Brain Research. 117:2000;69-74.
73. Russell V., de Villiers A., Sagvolden T., Lamm M., Taljaard J. Differences between electrically-, Ritalin- and D-amphetamine-stimulated release of [3H]dopamine from brain slices suggest impaired vesicular storage of dopamine in an animal model of attention-deficit hyperactivity disorder. Behavioral Brain Research. 94:1998;163-171.
74. Russell V.A., de Villiers A.S., Sagvolden T., Lamm M.C., Taljaard J.J. Methylphenidate affects striatal dopamine differently in an animal model for attention-deficit/hyperactivity disorder - the spontaneously hypertensive rat. Brain Research Bulletin. 53:2000;187-192.
75. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neuroscience and Biobehavioral Review. 24:2000;31-39.
76. Schabitz W., Weber J., Takano K., Sandage B., Locke K., Fischer M. The effects of prolonged treatment with citicoline in temporary experimental focal ischemia. Journal of Neurological Sciences. 138:1996;21-25.
77. Secades J.J., Frontera G. CDP-choline: Pharmacological and clinical review. Methods Find Experimental and Clinical Pharmacology. 17(Suppl. B):1995;2-54.
78. Sheard N.F., Zeisel S.H. Choline: An essential dietary nutrient? Nutrition. 5:1989;1-5.
79. Spiers P.A.D., Myers D.et al. Citicoline improves verbal memory in aging. Archives of Neurology. 53:1996;441-448.
80. Tazaki Y., Sakai F., Otomo E., Kutsuzawa T., Kameyama M., Omae T., Fujishima T. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke. 19:1988;211-216.
81. Terry A.V. Jr., Hernandez C.M., Buccafusco J.J., Gattu M. Deficits in spatial learning and nicotinic-acetylcholine receptors in older, spontaneously hypertensive rats. Neuroscience. 101:2000;357-368.
82. Teather, L. A., & Wurtman, R. J. (submitted). Dietary CDP-choline supplementation alleviates age-associated reference memory deficits in rats. Psychopharmacology.
83. Tohgi H., Utsugisawa K., Yoshimura M., Nagane Y., Mihara M. Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits α4 and β2 messenger RNA expression in postmortem human putamen. Implications for susceptibility to parkinsonism. Brain Research. 791:1998;186-189.
84. Weiss G.B. Metabolism and actions of CDP-choline as an endogenous compound and administered exogenously as citicoline. Life Science. 56(9):1995;637-660.
85. Wurtman R.J., Regan M., Ulus I., Yu L. Effect of oral CDP-choline on plasma choline and uridine levels in humans. Biochemical Pharmacology. 60:2000;89-92.
86. Wyss J.M., Fisk G., van Groen T. Impaired learning and memory in mature spontaneously hypertensive rats. Brain Research. 592:1992;135-140.
87. Wyss J.M., Chambless B.D., Kadish I., van Groen T. Age-related decline in water maze learning and memory in rats: Strain differences. Neurobiology of Aging. 21:2000;671-681.
88. Yamamoto M., Shimizu M., Okamiya H. Pharmacological actions of a new TRH analogue, YM-14673, in rats subjected to cerebral ischemia and anoxia. European Journal of Pharmacology. 181:1990;207-214.